ArticleNPJ precision oncology2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.
Anbarasu Kumaraswamy et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it